diammonium
glycyrrhizin
dg
salt
glycyrrhizin
gl
major
activ
compon
licoric
root
extract
variou
pharmacolog
activ
investig
inhibitori
effect
pseudorabi
viru
prv
infect
parallel
lithium
chlorid
licl
chemic
reagent
potenti
antivir
activ
compar
dg
inhibitori
abil
prv
infect
vitro
viru
plaquereduct
assay
pcr
rtpcr
analysi
indic
drug
inhibit
cell
infect
prv
moreov
addit
drug
result
fewer
apoptot
cell
prv
infect
glycyrrhizin
gl
import
bioactiv
compound
licoric
root
glycyrrhiza
radix
use
tradit
chines
medicin
herb
treat
hepat
due
antiinflammatori
properti
yuan
et
al
gl
activ
herp
simplex
type
varicellazost
viru
vzv
epsteinbarr
viru
ebv
human
cytomegaloviru
hepat
b
c
virus
influenza
viru
human
immunodefici
viru
hiv
sar
coronaviru
aras
et
al
baba
shigeta
cranc
et
al
hoever
et
al
ito
et
al
ito
et
al
lin
numazaki
et
al
pompei
et
al
sato
et
al
utsunomiya
et
al
diammonium
glycyrrhizin
dg
deriv
glycyrrhizin
modifi
two
carboxyl
group
posit
fig
dg
stabl
solubl
signific
bioactiv
gl
lithium
salt
use
therapeut
substanc
treatment
gout
rheumat
gout
bright
diseas
epilepsi
syphili
acut
mania
depress
episod
skinner
et
al
effect
lithium
salt
replic
herp
simplex
viru
vaccinia
viru
document
skinner
et
al
ziaie
kefalid
recent
report
lithium
chlorid
inhibit
infecti
bronchiti
viru
rna
coronaviru
cell
cultur
inhibit
due
cellular
rather
virucid
effect
harrison
et
al
pseudorabi
viru
prv
swine
neurotrop
herpesviru
common
genom
arrang
prv
use
model
organ
explor
herpesviru
biolog
swine
cattl
prv
infect
caus
aujeszki
diseas
ad
one
list
b
diseas
offic
intern
de
oie
although
pig
natur
reservoir
viru
prv
broad
host
rang
infect
mammal
avian
speci
klupp
et
al
suscept
speci
prv
infect
often
lethal
infect
anim
may
die
central
nervou
system
disord
tirabassi
enquist
prv
infect
pose
sever
threat
anim
husbandri
develop
effect
antivir
agent
one
import
strategi
decreas
occurr
prv
infect
addit
vaccin
studi
demonstr
inhibitori
effect
dg
licl
prv
infect
moreov
effect
drug
cell
apoptosi
induc
prv
investig
data
help
better
understand
antivir
mechan
compound
vero
cell
african
green
monkey
kidney
cell
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
shanghai
excel
biolog
inc
c
incub
contain
co
prv
strain
bartha
propag
vero
cell
vero
cell
monolay
cultur
plate
densiti
cellswel
wash
three
time
phosphatebuff
salin
pb
dg
zhengda
pharmaci
china
licl
sigma
st
loui
mo
dilut
serial
serumfre
dmem
inocul
well
wellseach
drug
mocktreat
cell
serv
control
cell
cultur
c
h
cell
morpholog
analyz
light
microscop
cell
monolay
plate
incub
drug
wash
pb
cell
incub
lwell
dmem
cultur
lwell
mtt
solut
c
h
wash
pb
l
dmso
ad
well
tray
shaken
gentli
min
dissolv
precipit
formazan
optic
densiti
od
valu
well
determin
use
plate
reader
test
wavelength
nm
cell
surviv
rate
calcul
drug
averag
od
valuecontrol
averag
od
valu
cell
surviv
rate
regard
nontox
concentr
drug
trypan
blue
stain
use
confirm
maximum
nontox
concentr
drug
briefli
ml
trypan
blue
mix
wv
pb
ad
dish
cell
incub
min
room
temperatur
percentag
viabl
cell
determin
divid
number
unstain
cell
total
number
cell
multipli
equat
follow
number
unstain
cellstot
number
cell
percent
viabl
cell
viru
titrat
subsequ
infect
analysi
perform
plaquereduct
assay
burleson
et
al
briefli
cell
monolay
plate
inocul
serial
dilut
virus
inoculum
replac
methylcellulos
dmem
h
absorpt
viru
cell
monolay
incub
c
h
overlay
medium
remov
cell
gentli
wash
three
time
pb
fix
formalin
pb
min
room
temperatur
crystal
violet
vv
dilut
etoh
pb
use
stain
cell
min
room
temperatur
clear
plaqu
number
visual
postwash
viru
titer
plaqueform
unit
pfu
calcul
experi
done
triplic
analyz
effect
drug
viru
per
se
pfuml
virus
treat
serial
dilut
drug
incub
c
h
vero
cell
infect
virus
subject
viru
plaqu
assay
analyz
inhibit
drug
prvinfect
cell
cell
plate
infect
pfuml
virus
c
h
wash
three
time
pb
cell
treat
serial
dilut
drug
c
h
postinfect
hpi
infect
virus
analyz
analyz
sensit
cell
drug
cell
plate
treat
serial
dilut
drug
c
h
cell
infect
pfuml
virus
wash
pb
cell
subject
plaqu
assay
confirm
effect
drug
prv
infect
vitro
polymeras
chain
reaction
pcr
use
assess
viral
load
use
prv
gdspecif
primer
cell
infect
drugtreat
virus
virusinfect
cell
treat
increas
concentr
licl
subject
dna
extract
commerci
kit
qiagen
germani
accord
publish
sequenc
prv
gd
gene
genbank
sens
primer
antisens
primer
use
amplifi
prv
gd
gene
bp
length
pcr
system
includ
l
dna
templat
l
gc
pcr
buffer
l
primer
l
dntp
l
rtaq
polymeras
l
steril
h
pcr
perform
c
min
cycl
c
c
c
min
final
extens
c
min
pcr
product
analyz
agaros
gel
electrophoresi
time
gapdh
bp
length
use
intern
standard
amplifi
sens
primer
antisens
primer
temperatur
profil
pcr
amplif
gene
c
min
c
min
c
min
follow
cycl
c
min
c
min
c
min
follow
final
extens
min
c
cell
infect
drugtreat
virus
prvinfect
cell
treat
increas
concentr
licl
subject
rna
extract
commerci
kit
qiagen
germani
revers
transcript
rt
pcr
perform
use
rtpcr
kit
takara
japan
antisens
primer
amplifi
either
gd
gapdh
gene
use
rt
subsequ
pcr
procedur
perform
cell
apoptosi
analyz
annexin
vfitc
kit
nanj
keygen
biotech
co
ltd
briefli
fitcconjug
annexin
v
lwell
propidium
iodid
pi
lwell
ad
cell
infect
drugtreat
virus
virusinfect
cell
treat
licl
plate
incub
room
temperatur
min
dark
prior
fluoresc
observ
detect
cell
earli
apoptosi
base
observ
soon
initi
apoptosi
cell
transloc
membran
phosphatidylserin
ps
inner
face
plasma
membran
cell
surfac
thereaft
ps
easili
detect
stain
fluoresc
conjug
annexin
v
protein
high
affin
ps
cell
stain
pi
detect
cellular
late
apoptosi
result
analyz
fluoresc
microscop
leica
germani
hpi
parallel
flow
cytometri
techniqu
use
analyz
cell
apoptosi
abovement
cell
sampl
trypsin
centrifug
rpm
min
cell
resuspend
l
bind
buffer
concentr
cellsml
wash
two
time
pb
rpm
min
l
fitcconjug
annexin
v
l
pi
ad
cell
incub
room
temperatur
min
dark
sampl
analyz
within
h
poststain
effect
dg
licl
vero
cell
viabil
prolifer
determin
maximum
nontox
concentr
dg
licl
dilut
dmem
medium
gml
mm
respect
abovement
drug
concentr
differ
drugtreat
cell
mocktreat
cell
term
cell
morpholog
cell
prolifer
significantli
affect
maximum
nontox
concentr
drug
indic
mtt
assay
fig
trypan
blue
stain
show
cell
complet
viabl
abovement
concentr
drug
fig
virus
use
infect
cell
treat
drug
plaquereduct
assay
show
drug
inhibit
viru
infect
dosedepend
manner
maximum
nontox
concentr
drug
inhibit
rate
licl
dg
prv
infect
cell
cultur
reach
fig
effect
drug
prvinfect
cell
analyz
use
plaquereduct
assay
reduct
viru
infect
observ
differ
sampl
dg
treatment
group
data
shown
effect
licl
analyz
format
viru
plaqu
inhibit
dosedepend
manner
fig
cell
monolay
treat
licl
dg
virus
appli
cell
plaquereduct
assay
fig
trypan
blue
stain
mocktreat
cell
cell
treat
maximum
nontox
concentr
drug
subject
trypan
blue
stain
repres
comparison
provid
fig
pcr
target
amplif
prv
gd
gene
cell
infect
drugtreat
virus
subject
pcr
use
prv
gdspecif
primer
effect
licl
dg
gene
amplif
shown
panel
b
respect
prvinfect
cell
treat
licl
subject
pcr
detect
gd
gene
pcr
result
shown
panel
c
housekeep
gene
gapdh
serv
intern
refer
done
h
later
show
inhibitori
effect
observ
either
drug
data
shown
viral
genom
load
assess
pcr
analysi
gd
gene
inhibit
partial
mm
licl
gml
dg
inhibit
complet
mm
licl
gml
dg
gd
gene
amplif
also
inhibit
prvinfect
cell
treat
licl
posit
pcr
product
mm
licl
treatment
group
amplif
housekeep
gene
gapdh
posit
pcr
analys
fig
confirm
effect
compound
gd
gene
rtpcr
perform
analyz
amount
amplifi
dna
gd
gene
shown
fig
rtpcr
analysi
gave
rise
similar
result
pcr
analysi
cell
apoptosi
analyz
annexin
vfitc
pi
dual
stain
kit
show
prvinfect
cell
display
earli
late
apoptosi
late
apoptosi
rate
cell
infect
drugtreat
virus
decreas
drug
dosedepend
manner
late
apoptosi
virusinfect
cell
treat
licl
inhibit
significantli
contrast
dg
prevent
virusinfect
cell
apoptosi
result
agreement
viru
infect
analysi
howev
earli
hpi
earli
apoptosi
cell
affect
lightli
repres
stain
pictur
regard
effect
drug
maximum
nontox
concentr
cell
apoptosi
shown
fig
inhibit
rate
late
apoptosi
shown
fig
c
confirm
cell
apoptosi
induc
prv
flow
cytometri
techniqu
util
shown
fig
maximum
nontox
concentr
drug
inhibitori
activ
prvinduc
cell
apoptosi
mani
antivir
agent
test
effect
human
herp
simplex
virus
counterpart
prv
subfamili
alphaherpesvirina
herpesvirida
famili
de
clercq
naesen
de
clercq
sergeri
boivin
cheng
et
al
due
potenti
threat
prv
infect
anim
husbandri
necessari
develop
effect
antivir
agent
prv
infect
report
licl
abl
inhibit
replic
dna
viru
herp
simplex
interf
herp
simplex
virionassoci
inhibit
host
protein
synthesi
skinner
et
al
ziaie
kefalid
studi
investig
effect
reagent
prv
infect
vitro
mode
action
result
show
prv
infect
decreas
dosedepend
manner
treatment
licl
either
virusinfect
cell
viru
per
se
licl
known
inhibitori
effect
rna
coronaviru
infecti
bronchiti
viru
ibv
cell
cultur
inhibit
due
cellular
rather
virucid
effect
harrison
et
al
therefor
licl
may
perspect
broadspectrum
antivir
apoptosi
analysi
indic
prv
infect
initi
cell
apoptosi
drug
use
studi
inhibit
virusinduc
cell
apoptosi
although
cell
earli
apoptosi
affect
drug
treatment
also
investig
cell
apoptosi
hpi
gave
similar
result
hpi
report
point
mutat
atp
bind
site
prv
protein
kinas
prevent
bad
phosphoryl
cell
surviv
apoptosi
appear
mapk
jnksapk
signal
involv
prv
apoptosi
deruel
et
al
yeh
et
al
mechan
regard
effect
drug
apoptosi
pathway
investig
flow
cytometri
analysi
also
suggest
licl
signific
effect
dg
term
inhibitori
activ
cell
apoptosi
microscop
score
fluoresc
sampl
flow
cytometr
data
indic
similar
reduct
trend
cell
apoptosi
addit
drug
howev
differ
degre
reduct
apoptosi
discrep
might
attribut
differ
method
per
se
criterion
cell
statu
system
error
etc
pcr
result
show
amplifi
amount
prv
gd
gene
decreas
increas
drug
concentr
manifest
drug
appear
reduc
viral
genom
load
via
unresolv
mechan
rtpcr
result
suggest
compound
interf
viral
gd
gene
possibl
observ
antiapoptot
effect
dg
licl
prv
infect
indirect
due
reduc
viru
replic
caus
drug
futur
work
tri
elucid
whether
inhibit
prv
infect
licl
attribut
direct
virucid
effect
inhibitori
activ
replic
prv
dg
salt
deriv
gl
may
similar
antivir
activ
gl
studi
especi
interest
understand
mode
action
regard
inhibitori
activ
prv
infect
vitro
report
gl
activ
herp
virus
vzv
ebv
lin
howev
abovement
experi
ebv
incub
mm
gl
c
h
ebv
infect
analyz
signific
reduct
viral
infect
observ
lin
author
assum
antivir
activ
gl
attribut
direct
inactiv
viru
anoth
report
found
mm
gl
could
inactiv
herp
simplex
viru
particl
irrevers
min
pompei
et
al
data
show
pretreat
virus
dg
inhibit
cell
infect
prv
dosedepend
manner
suppos
differ
report
mode
action
dggl
may
attribut
either
differ
natur
individu
viru
herp
viru
famili
discrep
concentr
drug
appli
assay
compar
licl
dg
inhibit
prv
infect
viru
adsorpt
seem
drug
virucid
prv
find
would
interest
effect
gl
cellular
protein
kinas
c
p
report
abe
et
al
ito
fig
cell
apoptosi
analysi
flow
cytometri
cell
stain
annexin
vfitc
pi
either
infect
maximum
nontox
concentr
drugtreat
virus
virusinfect
cell
treat
licl
maximum
nontox
concentr
cell
apoptosi
analyz
flow
cytometri
data
present
dualparamet
annexin
v
versu
pi
upper
right
area
apoptot
cell
apoptosi
rate
cell
indic
ohtsuki
iahida
propos
antihiv
effect
gl
may
attribut
inhibitori
effect
cellular
protein
kinas
studi
whilst
dg
observ
effect
cell
morpholog
virusinfect
cell
effect
cell
signal
could
easili
lead
chang
viru
replic
hsiang
et
al
therefor
investig
effect
dg
data
show
pretreat
cell
drug
result
decreas
prv
infect
suggest
cellular
factor
includ
cellular
receptor
prv
might
sensit
drug
like
licl
dg
show
good
inhibitori
effect
cell
apoptosi
incub
drug
virus
data
indic
prv
infect
induc
cell
apoptosi
addit
drug
also
result
fewer
apoptot
cell
prv
infect
